Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC-Reference-Cited by-同舟云学术

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC

Published:2018-12-16 Issue:11 Volume:144 Page:2677-2682
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Wang Jinguang¹,Li Xingya²,Xue Xingyang³,Ou Qiuxiang⁴^ORCID,Wu Xue⁴,Liang Ying⁵,Wang Xiaonan⁶,You Ming⁶,Shao Yang W.⁴⁷,Zhang Zhihong⁸,Zhang Shucai⁹

Affiliation:

1. Department of Thoracic SurgeryFirst Affiliated Hospital of Dalian Medical University Dalian Liaoning China

2. Department of OncologyFirst Affiliated Hospital of Zhengzhou University Zhengzhou Henan China

3. Department of Thoracic SurgeryAffiliated Cancer Hospital & Institute of Guangzhou Medical University

4. Translational Medicine Research InstituteGeneseeq Technology Inc. Toronto Ontario Canada

5. Department of Medical OncologySun Yat‐sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong China

6. Nanjing Geneseeq Technology Inc. Nanjing Jiangsu China

7. School of Public HealthNanjing Medical University Nanjing Jiangsu China

8. Department of PathologyThe First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China

9. Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, 9 Beiguan Avenue Tongzhou Beijing 101149 China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.31895

Reference16 articles.

1. Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

2. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

4. EGFR Mutations and Lung Cancer

5. Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR kinase domain duplication in lung adenocarcinoma with systemic and intracranial response to a double-dose of furmonertinib: a case report and literature review;Frontiers in Oncology;2024-06-21

2. Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors;The Oncologist;2024-05-31

3. Expanding the Clinical Utility of Targeted RNA Sequencing Panels beyond Gene Fusions to Complex, Intragenic Structural Rearrangements;Cancers;2023-09-02

4. Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC;Journal of Thoracic Oncology;2023-04

5. Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer;Biomolecules;2023-01-20